Genetics and implications in perioperative analgesia

Best Practice and Research: Clinical Anaesthesiology

Volumn 28, Issue 2, 2014, Pages 153-166

  Trescot, Andrea M ^a  

^a Pain and Headache Center   (United States)

Author keywords

ABCB1; anesthesia genetics; COMT; CYP2B6; CYP2D6; CYP3A4; drug drug interactions; drug gene interactions; GABA; MC1R; opioid metabolism; OPRK1; OPRM1; pharmacogenetics; UGT2B7

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; BARBITURIC ACID DERIVATIVE; CAFFEINE; CELECOXIB; CLOMIPRAMINE; CLOZAPINE; CYCLOBENZAPRINE; DESIPRAMINE; DIAZEPAM; DULOXETINE; FLUVOXAMINE; IBUPROFEN; IMIPRAMINE; KETAMINE; LIDOCAINE; MELATONIN; METHADONE; NABUMETONE; OPIATE; PARACETAMOL; PIROXICAM; SERTRALINE; TESTOSTERONE; THEOPHYLLINE; TIZANIDINE; TOPIRAMATE; UNINDEXED DRUG; VALPROIC ACID; WARFARIN; ANALGESIC AGENT; NARCOTIC ANALGESIC AGENT;

ANALGESIA; ARTICLE; DISEASE PREDISPOSITION; DRUG METABOLISM; ENVIRONMENTAL FACTOR; ETHNOGENETICS; GENETICS; HUMAN; NOCICEPTION; PERIOPERATIVE ANALGESIA; PRIORITY JOURNAL; SMOKING; ANESTHESIA; METABOLISM; PAIN; PROCEDURES;

ANALGESIA; ANALGESICS; ANALGESICS, OPIOID; ANESTHESIA; GENETICS; HUMANS; PAIN;

EID: 84903719132     PISSN: 15216896     EISSN: 1532169X     Source Type: Journal    
DOI: 10.1016/j.bpa.2014.03.004     Document Type: Review

References (88)

1. P. Klepstad, S. Kaasa, and M. Skauge et al. Pain intensity and side effects during titration of morphine to cancer patients using a fixed schedule dose escalation Acta Anaesthesiol Scand - Clin Trial Res Support, Non-U.S. Gov't 44 6 2000 Jul 656 664 (Pubitemid 30413411)
2. L.E. Mather, and C.J. Glynn The minimum effective analgetic blood concentration of pethidine in patients with intractable pain Br J Clin Pharmacol 14 3 1982 Sep 385 390 (Pubitemid 13139136)
3. J.R. Ross, D. Rutter, and K. Welsh et al. Clinical response to morphine in cancer patients and genetic variation in candidate genes Pharmacogenomics J 5 5 2005 324 336 (Pubitemid 41486231)
4. M.L. Honkasalo, J. Kaprio, and T. Winter et al. Migraine and concomitant symptoms among 8167 adult twin pairs Headache 35 2 1995 Feb 70 78
5. D.K. Ziegler, Y.M. Hur, and T.J. Bouchard Jr. et al. Migraine in twins raised together and apart Headache 38 6 1998 Jun 417 422 (Pubitemid 28399170)
6. D.A. Svensson, B. Larsson, and E. Waldenlind et al. Shared rearing environment in migraine: results from twins reared apart and twins reared together Headache 43 3 2003 Mar 235 244 (Pubitemid 36348770)
7. B. Bengtsson, and J. Thorson Back pain: a study of twins Acta Genet Med Gemellol (Roma) 40 1 1991 83 90
8. P.H. Ferreira, P. Beckenkamp, and C.G. Maher et al. Nature or nurture in low back pain? Results of a systematic review of studies based on twin samples Eur J Pain 2013 957 971
9. G. Livshits, M. Popham, and I. Malkin et al. Lumbar disc degeneration and genetic factors are the main risk factors for low back pain in women: the UK Twin Spine Study Ann Rheum Dis 70 10 2011 Oct 1740 1745
10. S.A. Treloar, N.G. Martin, and A.C. Heath Longitudinal genetic analysis of menstrual flow, pain, and limitation in a sample of Australian twins Behav Genet 28 2 1998 Mar 107 116 (Pubitemid 28208345)
11. M.S. Angst, N.G. Phillips, and D.R. Drover et al. Pain sensitivity and opioid analgesia: a pharmacogenomic twin study Pain 153 7 2012 Jul 1397 1409
12. M. Berkovitch, L. Copeliovitch, and T. Tauber et al. Hereditary insensitivity to pain with anhidrosis Pediatr Neurol 19 3 1998 Sep 227 229 (Pubitemid 28476280)
13. S.A. Slaugenhaupt, A. Blumenfeld, and S.P. Gill et al. Tissue-specific expression of a splicing mutation in the IKBKAP gene causes familial dysautonomia Am J Hum Genet 68 3 2001 Mar 598 605 (Pubitemid 32202755)
14. J. Shapira, Y. Zilberman, and A. Becker Lesch-Nyhan syndrome: a non-extracting approach to prevent mutilation Dent Health (London) 25 6 1987 Dec-Jan 6 7
15. R. Fu, and H.A. Jinnah Genotype-phenotype correlations in Lesch-Nyhan disease: moving beyond the gene J Biol Chem 287 5 2012 Jan 27 2997 3008
16. A. Kuzniacka, J. Wierzba, and M. Ratajska et al. Spectrum of NIPBL gene mutations in Polish patients with Cornelia de Lange syndrome J Appl Genet 54 1 2013 Feb 27 33
17. P. Paschou The genetic basis of Gilles de la Tourette syndrome Neurosci Biobehav Rev 2013 1026 1039
18. J.J. Jim, N. Noponen-Hietala, and K.M. Cheung et al. The TRP2 allele of COL9A2 is an age-dependent risk factor for the development and severity of intervertebral disc degeneration Spine 30 24 2005 Dec 15 2735 2742 (Pubitemid 43011033)
19. J.F. Sanchez Munoz-Torrero, P. Barquilla, and R. Velasco et al. Adverse drug reactions in internal medicine units and associated risk factors Eur J Clin Pharmacol 66 12 2010 Dec 1257 1264
20. A. Hisaka, Y. Ohno, and T. Yamamoto et al. Prediction of pharmacokinetic drug-drug interaction caused by changes in cytochrome P450 activity using in vivo information Pharmacol Ther 125 2 2010 Feb 230 248
21. M. Ingelman-Sundberg Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future Trends Pharmacol Sci 25 4 2004 Apr 193 200 (Pubitemid 38519910)
22. M.W. Linder, and R. Valdes Fundamentals and applications of pharmacogenetics for the clinical laboratory Ann Clin Lab Sci 29 2 1999 140 149 (Pubitemid 29177631)
23. K.A. Phillips, D.L. Veenstra, and E. Oren et al. Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review JAMA 286 18 2001 Nov 14 2270 2279 (Pubitemid 33063150)
24. I. Cascorbi Pharmacogenetics of cytochrome p4502D6: genetic background and clinical implication Eur J Clin Invest 33 Suppl. 2 2003 Nov 17 22
25. L.D. Bradford CYP2D6 allele frequency in European Caucasians, Asians, Africans and their decendants Pharmacogenomics 3 2002 229 243 (Pubitemid 34223859)
26. K.J. Karczewski, R. Daneshjou, and R.B. Altman Chapter 7: pharmacogenomics PLoS Comput Biol 8 12 2012 e1002817
27. A. Foster, E. Mobley, and Z. Wang Complicated pain management in a CYP450 2D6 poor metabolizer Pain Pract 7 4 2007 Dec 352 356 (Pubitemid 350142307)
28. M.P. Goetz, J.M. Rae, and V.J. Suman et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes J Clin Oncol 23 36 2005 Dec 20 9312 9318
29. M. Benmebarek, C. Devaud, and M. Gex-Fabry et al. Effects of grapefruit juice on the pharmacokinetics of the enantiomers of methadone Clin Pharmacol Ther 76 1 2004 Jul 55 63 (Pubitemid 38844734)
30. L.S. Wang, G. Zhou, and B. Zhu et al. St John's wort induces both cytochrome P450 3A4-catalyzed sulfoxidation and 2C19-dependent hydroxylation of omeprazole Clin Pharmacol Ther 75 3 2004 Mar 191 197 (Pubitemid 38314868)
31. Z. Wang, J.C. Gorski, and M.A. Hamman et al. The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity Clin Pharmacol Ther 70 4 2001 Oct 317 326 (Pubitemid 33022472)
32. D. Eich-Hochli, R. Oppliger, and K.P. Golay et al. Methadone maintenance treatment and St. John's Wort - a case report Pharmacopsychiatry 36 1 2003 Jan 35 37 (Pubitemid 36384633)
33. J. Wahawisan, S. Kolluru, and T. Nguyen et al. Methadone toxicity due to smoking cessation - a case report on the drug-drug interaction involving cytochrome P450 isoenzyme 1A2 Ann Pharmacother 45 6 2011 Jun e34
34. W.E. Ackerman, and M. Ahmad Effect of cigarette smoking on serum hydrocodone levels in chronic pain patients J Ark Med Soc 104 1 2007 19 21
35. D.F. Kisor, C. Munro, and E. Loudermilk Pharmacogenomics and the most commonly prescribed drugs of 2011 Pharm Times 78 12 2012
36. The human cytochrome P450 (CYP) allele nomenclature database. Available from: http://www.cypalleles.ki.se/ [cited 9/28/13].
37. S.C. Armstrong, and K.L. Cozza Pharmacokinetic drug interactions of morphine, codeine, and their derivatives: theory and clinical reality, part II Psychosomatics 44 6 2003 Nov-Dec 515 520 (Pubitemid 37352231)
38. J. Kirchheiner, H. Schmidt, and M. Tzvetkov et al. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication Pharmacogenomics J 7 4 2007 Aug 257 265 (Pubitemid 47202488)
39. S. Grond, and A. Sablotzki Clinical pharmacology of tramadol Clin Pharmacokinet 43 13 2004 879 923 (Pubitemid 39447033)
40. H.L. Kaplan, U.E. Busto, and G.J. Baylon et al. Inhibition of cytochrome P450 2D6 metabolism of hydrocodone to hydromorphone does not importantly affect abuse liability J Pharmacol Exp Ther 281 1 1997 Apr 103 108 (Pubitemid 27203056)
41. S.V. Otton, M. Schadel, and S.W. Cheung et al. CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone Clin Pharmacol Ther 54 5 1993 463 472 (Pubitemid 23349082)
42. N.H. Barakat, R.S. Atayee, and B.M. Best et al. Relationship between the concentration of hydrocodone and its conversion to hydromorphone in chronic pain patients using urinary excretion data J Anal Toxicol 36 4 2012 May 257 264
43. C.F. Samer, Y. Daali, and M. Wagner et al. Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety Br J Pharmacol 160 4 2010 Jun 919 930
44. R. Poyhia, T. Seppala, and K.T. Olkkola et al. The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects Br J Clin Pharmacol 33 6 1992 Jun 617 621
45. Z. Yang, K.L. Arheart, and R. Morris et al. CYP2D6 poor metabolizer genotype and smoking predict severe postoperative pain in female patients on arrival to the recovery room Pain Med 13 4 2012 Apr 604 609
46. K.A. Candiotti, Z. Yang, and Y. Rodriguez et al. The impact of CYP2D6 genetic polymorphisms on postoperative morphine consumption Pain Med 10 5 2009 Jul-Aug 799 805
47. H. Mulder, E.R. Heerdink, and E.E. van Iersel et al. Prevalence of patients using drugs metabolized by cytochrome P450 2D6 in different populations: a cross-sectional study Ann Pharmacother 41 3 2007 Mar 408 413 (Pubitemid 46536030)
48. A. Seeringer, and J. Kirchheiner Pharmacogenetics-guided dose modifications of antidepressants Clin Lab Med 28 4 2008 Dec 619 626
49. E. Kadiev, V. Patel, and P. Rad et al. Role of pharmacogenetics in variable response to drugs: focus on opioids Expert Opin Drug Metab Toxicol 4 1 2008 Jan 77 91 (Pubitemid 351234102)
50. C. Iribarne, F. Berthou, and S. Baird et al. Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes Chem Res Toxicol 9 2 1996 Mar 365 373 (Pubitemid 26079977)
51. Y. Oda, and E.D. Kharasch Metabolism of methadone and levo-alpha-acetylmethadol (LAAM) by human intestinal cytochrome P450 3A4 (CYP3A4): potential contribution of intestinal metabolism to presystemic clearance and bioactivation J Pharmacol Exp Ther 298 3 2001 Sep 1021 1032 (Pubitemid 32761918)
52. R.A. Totah, P. Sheffels, and T. Roberts et al. Role of CYP2B6 in stereoselective human methadone metabolism Anesthesiology 108 3 2008 Mar 363 374 (Pubitemid 351304229)
53. O. Levran, E. Peles, and S. Hamon et al. CYP2B6 SNPs are associated with methadone dose required for effective treatment of opioid addiction Addict Biol 18 4 2011 709 716
54. I. Loryan, M. Lindqvist, and I. Johansson et al. Influence of sex on propofol metabolism, a pilot study: implications for propofol anesthesia Eur J Clin Pharmacol 68 4 2012 Apr 397 406
55. Y.C. Liu, and W.S. Wang Human mu-opioid receptor gene A118G polymorphism predicts the efficacy of tramadol/acetaminophen combination tablets (ultracet) in oxaliplatin-induced painful neuropathy Cancer 118 6 2011 Mar 15 1718 1725
56. Y. Zhang, D. Wang, and A.D. Johnson et al. Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G J Biol Chem 280 38 2005 Sep 23 32618 32624 (Pubitemid 41368304)
57. C.C. Reyes-Gibby, S. Shete, and T. Rakvag et al. Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT gene Pain 130 1-2 2007 Jul 25 30 (Pubitemid 46850782)
58. R.W. Gear, N.C. Gordon, and M. Hossaini-Zadeh et al. A subanalgesic dose of morphine eliminates nalbuphine anti-analgesia in postoperative pain J Pain 9 4 2008 Apr 337 341
59. X. Xuei, D. Dick, and L. Flury-Wetherill et al. Association of the kappa-opioid system with alcohol dependence Mol Psychiatry 11 11 2006 Nov 1016 1024 (Pubitemid 44631644)
60. E.R. Butelman, V. Yuferov, and M.J. Kreek kappa-opioid receptor/dynorphin system: genetic and pharmacotherapeutic implications for addiction Trends Neurosci 35 10 2012 Oct 587 596
61. V. Yuferov, D. Fussell, and K.S. LaForge et al. Redefinition of the human kappa opioid receptor gene (OPRK1) structure and association of haplotypes with opiate addiction Pharmacogenetics 14 12 2004 Dec 793 804 (Pubitemid 40054335)
62. H.A. Tejeda, T.S. Shippenberg, and R. Henriksson The dynorphin/kappa- opioid receptor system and its role in psychiatric disorders Cell Mol Life Sci 69 6 2011 Mar 857 896
63. S.N. de Wildt, G.L. Kearns, and J.S. Leeder et al. Glucuronidation in humans. Pharmacogenetic and developmental aspects Clin Pharmacokinet 36 6 1999 Jun 439 452 (Pubitemid 29317491)
64. A.M. Trescot, S. Datta, and M. Lee et al. Opioid pharmacology Pain Physician 11 Opioid Special issue 2008 S133 S153
65. M.T. Donato, S. Montero, and J.V. Castell et al. Validated assay for studying activity profiles of human liver UGTs after drug exposure: inhibition and induction studies Anal Bioanal Chem 396 6 2010 Mar 2251 2263
66. T.T. Rakvag, J.R. Ross, and H. Sato et al. Genetic variation in the catechol-O-methyltransferase (COMT) gene and morphine requirements in cancer patients with pain Mol Pain 4 2008 64
67. H. Kim, J.K. Neubert, and A. San Miguel et al. Genetic influence on variability in human acute experimental pain sensitivity associated with gender, ethnicity and psychological temperament Pain 109 3 2004 Jun 488 496 (Pubitemid 38638726)
68. L. Diatchenko, G.D. Slade, and A.G. Nackley et al. Genetic basis for individual variations in pain perception and the development of a chronic pain condition Hum Mol Genet 14 1 2005 Jan 1 135 143 (Pubitemid 40123469)
69. C.F. Guardia, and R.A. Egan Temporomandibular disorders Medscape 2012 Available from: http://emedicine.medscape.com/article/1143410-overview [updated 2012 1/11/12; cited 9/28/13]
70. L. Diatchenko, A.D. Anderson, and G.D. Slade et al. Three major haplotypes of the beta2 adrenergic receptor define psychological profile, blood pressure, and the risk for development of a common musculoskeletal pain disorder Am J Med Genet B Neuropsychiatr Genet 141B 5 2006 Jul 5 449 462 (Pubitemid 44024438)
71. H.A. Nash In vivo genetics of anaesthetic action Br J Anaesth 89 1 2002 Jul 143 155 (Pubitemid 34778110)
72. O. Levran, K. O'Hara, and E. Peles et al. ABCB1 (MDR1) genetic variants are associated with methadone doses required for effective treatment of heroin dependence Hum Mol Genet 17 14 2008 Jul 15 2219 2227 (Pubitemid 351916578)
73. A. Rhodin, A. Gronbladh, and H. Ginya et al. Combined analysis of circulating beta-endorphin with gene polymorphisms in OPRM1, CACNAD2 and ABCB1 reveals correlation with pain, opioid sensitivity and opioid-related side effects Mol Brain 6 1 2013 Feb 12 8
74. A.T. Sia, B.L. Sng, and E.C. Lim et al. The influence of ATP-binding cassette sub-family B member-1 (ABCB1) genetic polymorphisms on acute and chronic pain after intrathecal morphine for caesarean section: a prospective cohort study Int J Obstet Anesth 19 3 2010 Jul 254 260
75. J.S. Mogil, S.G. Wilson, and E.J. Chesler et al. The melanocortin-1 receptor gene mediates female-specific mechanisms of analgesia in mice and humans Proc Natl Acad Sci U S A 100 8 2003 Apr 15 4867 4872 (Pubitemid 36457820)
76. B. Oertel, and J. Lotsch Genetic mutations that prevent pain: implications for future pain medication Pharmacogenomics 9 2 2008 Feb 179 194 (Pubitemid 351566942)
77. M. Cohen, S. Sadhasivam, and A.A. Vinks Pharmacogenetics in perioperative medicine Curr Opin Anaesthesiol 25 4 2012 Aug 419 427
78. J.L. Rees Genetics of hair and skin color Annu Rev Genet 37 2003 67 90 (Pubitemid 38041421)
79. 2-receptor agonists and proton-pump inhibitors J Anal Toxicol 37 8 2013 Oct 476 485
80. T. Fukasawa, A. Suzuki, and K. Otani Effects of genetic polymorphism of cytochrome P450 enzymes on the pharmacokinetics of benzodiazepines J Clin Pharm Ther 32 4 2007 Aug 333 341 (Pubitemid 47063159)
81. K.A. Candiotti, D.J. Birnbach, and D.A. Lubarsky et al. The impact of pharmacogenomics on postoperative nausea and vomiting: do CYP2D6 allele copy number and polymorphisms affect the success or failure of ondansetron prophylaxis? Anesthesiology 102 3 2005 Mar 543 549 (Pubitemid 40315143)
82. Y.S. Lee, H. Kim, and T.X. Wu et al. Genetically mediated interindividual variation in analgesic responses to cyclooxygenase inhibitory drugs Clin Pharmacol Ther 79 5 2006 May 407 418
83. M.W. Linder, S. Looney, and J.E. Adams 3rd et al. Warfarin dose adjustments based on CYP2C9 genetic polymorphisms J Thromb Thrombolysis 14 3 2002 Dec 227 232 (Pubitemid 37069306)
84. G. D'Andrea, R.L. D'Ambrosio, and P. Di Perna et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin Blood 105 2 2005 Jan 15 645 649 (Pubitemid 40070748)
85. E.A. Sconce, T.I. Khan, and H.A. Wynne et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen Blood 106 7 2005 Oct 1 2329 2333 (Pubitemid 41510803)
86. A.M. Trescot Local anesthetic resistance Pain Physician 6 3 2003 Jul 291 293
87. R. Landau, J.C. Kraft, and L.Y. Flint et al. An experimental paradigm for the prediction of Post-Operative Pain (PPOP) J Vis Exp 35 2010
88. http://www.quackwatch.org/01QuackeryRelatedTopics/Tests/genomics.html [cited 9/28/13].